Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

DAWN·NASDAQ

$21.53

+0.0000%
HealthcareBiotechnology

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$2.22B
EPS-1.0400
P/E Ratio-20.70
Earnings Date05/13/2026

dawn

Sales/Maturities of Investments

Last Annual Value

874.25M

3-Year CAGR

85%

5-Year CAGR

%

10-Year CAGR

%

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Competitors Analysis of Sales/Maturities of Investments

DAWN · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
874.25M
15.0%N/AN/A 
411.72M
11.6%10.5%11.5%
4.05B
25.3%133.0%63.1%
173.86M
N/AN/AN/A
201.71M
100.6%N/AN/A
ARVN logo
Arvinas, Inc.
NASDAQ:ARVN
763.70M
-13.1%11.9%46.4%
ERAS logo
Erasca, Inc.
NASDAQ:ERAS
261.03M
2.1%34.1%N/A
1.20B
-18.3%31.9%N/A
386.48M
-4.5%13.4%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
113.60M
166.5%N/AN/A
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Fair Value Envelope

DAWN · NASDAQ

Our analysis suggests that DAWN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $21.53, this represents a potential HIDDEN relative to our calculated worth for Day One Biopharmaceuticals, Inc..

Intrinsic Value
Current Price: $21.53